

RACE IT – Neoadjuvante Radioimmuntherapie beim lokal fortgeschrittenen Blasenkarzinom

Sebastian C. Schmid für das RACE IT Studienteam

Literatur

1. Robert Koch-Institut (Hrsg), u.d.G.d.e.K.i.D.e.V.H. Krebs in Deutschland 2011/2012. 2015: Berlin
2. Hautmann RE et al. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. *J Urol* 2006; 176(2): 486–92
3. Schmid SC et al. Prognostic value of computed tomography before radical cystectomy in patients with invasive bladder cancer: imaging predicts survival. *World J Urol* 2015
4. ABC meta-analysis collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. *Eur Urol* 2005; 48: 202–5
5. Witjes JA (Chair) et al. EAU Guideline on Muscle-invasive and Metastatic Bladder Cancer. EAU Guidelines 2017
6. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, in AWMF-Registrierungsnummer 032/038OL. 2016
7. Schmid SC et al. [Immuno-oncological approaches in the perioperative therapy of muscle invasive bladder cancer]. *Urologe A* 2020; 59: 790–6
8. Van Limbergen EJ et al. Combining radiotherapy with immunotherapy: the past, the present and the future. *Br J Radiol* 2017; 90(1076): 20170157
9. Zeng J et al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. *Int J Radiat Oncol Biol Phys* 2013; 86: 343–9
10. Gong J et al. Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. *J Immunother Cancer* 2018; 6: 46
11. Park SS et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. *Cancer Immunol Res* 2015; 3: 610–9
12. Schmid SC et al. Radiation therapy before radical cystectomy combined with immunotherapy in locally advanced bladder cancer - study protocol of a prospective, single arm, multicenter phase II trial (RACE IT). *BMC cancer* 2020; 20: 8